Shanghai Medicilon Inc Total Liabilities
Shanghai Medicilon Inc total liabilities. Based on the latest financial reports, Shanghai Medicilon Inc (688202) has total liabilities worth CN¥878.17 Million CNY (≈ $128.50 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Shanghai Medicilon Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Medicilon Inc (2016–2025)
Total liabilities of Shanghai Medicilon Inc from 2016 to 2025. This chart illustrates how Shanghai Medicilon Inc's total liabilities have evolved over time, based on quarterly financial data.
Shanghai Medicilon Inc Competitors by Total Liabilities
The table below lists competitors of Shanghai Medicilon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suning Commerce Group Co Ltd
SHE:002024
|
China | CN¥91.43 Billion |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
China | CN¥3.59 Billion |
|
Bilia AB (publ)
ST:BILI-A
|
Sweden | Skr15.91 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $27.58 Million |
|
YFY Inc
TW:1907
|
Taiwan | NT$82.63 Billion |
|
Scatec Solar OL
OL:SCATC
|
Norway | Nkr37.71 Billion |
|
Youngone Holdi
KO:009970
|
Korea | ₩1.61 Trillion |
|
Shanghai Electric Wind Power Group Co. Ltd. A
SHG:688660
|
China | CN¥29.88 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Shanghai Medicilon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Shanghai Medicilon Inc.
Liquidity & Leverage Metrics
Shanghai Medicilon Inc Total Liabilities Ratios Explained
Shanghai Medicilon Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Medicilon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual total liabilities of Shanghai Medicilon Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥687.85 Million ≈ $100.65 Million |
+0.70% |
| 2024-12-31 | CN¥683.10 Million ≈ $99.96 Million |
-9.53% |
| 2023-12-31 | CN¥755.07 Million ≈ $110.49 Million |
+3.89% |
| 2022-12-31 | CN¥726.80 Million ≈ $106.35 Million |
+55.94% |
| 2021-12-31 | CN¥466.06 Million ≈ $68.20 Million |
+103.81% |
| 2020-12-31 | CN¥228.67 Million ≈ $33.46 Million |
+79.02% |
| 2019-12-31 | CN¥127.73 Million ≈ $18.69 Million |
+2.13% |
| 2018-12-31 | CN¥125.06 Million ≈ $18.30 Million |
+22.27% |
| 2017-12-31 | CN¥102.29 Million ≈ $14.97 Million |
+3.52% |
| 2016-12-31 | CN¥98.81 Million ≈ $14.46 Million |
-- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow ch… Read more